The FDA's Office of Therapeutic Products witnessed abrupt senior staff changes, including the administrative leave of Nicole Verdun, MD, and deputy Rachael Anatol, PhD. Verdun was instrumental in approving the first in vivo CRISPR gene editing therapy for a rare urea cycle disorder. The personnel shifts have led to concerns among industry observers about regulatory stability for cell and gene therapies. Despite some stock market declines in cell and gene therapy firms, the impact was less severe than initially feared. The recent turmoil follows previous leadership disputes at the FDA's Center for Biologics Evaluation and Research.